Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 4Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 126Carboplatin 108Pemetrexed 76Paclitaxel 76Cisplatin 73Nivolumab 56Docetaxel 53Erlotinib Hydrochloride 50Gemcitabine 49Radiotherapy 48Bevacizumab 32osimertinib 31Cetuximab 29atezolizumab 25Cyclophosphamide 25durvalumab 24130-nm albumin-bound paclitaxel 22Oxaliplatin 19Fluorouracil 18Taxes 17Radiosurgery 17fludarabine 16Magnetic Resonance Spectroscopy 16Gefitinib 16Ipilimumab 15Vinorelbine 14Leucovorin 14Albumin-Bound Paclitaxel 14Vorinostat 13Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Non-Small-Cell Lung × LY3023414 × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

NCT02079636 2020-09-11

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 1 Completed
142 enrolled 36 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡